S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Better Than Oil Stocks (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Better Than Oil Stocks (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Better Than Oil Stocks (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Better Than Oil Stocks (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
$0.80
▼
$1.23
52-Week Range
N/A
Volume
5,211 shs
Average Volume
1,824 shs
Market Capitalization
$1.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media

ADXS stock logo

About Ayala Pharmaceuticals (NASDAQ:ADXS) Stock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.


ADXS Stock News Headlines

September 29, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com
September 21, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com
October 1, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
August 10, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 3, 2023 | investing.com
Ayala Pharmaceuticals Inc (ADXS)
August 1, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
July 27, 2023 | finance.yahoo.com
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 5, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
October 1, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
June 5, 2023 | finance.yahoo.com
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 20, 2023 | health.usnews.com
Armando Ayala
April 27, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 13, 2023 | uk.finance.yahoo.com
Ayala Pharmaceuticals, Inc. (ADXS)
April 12, 2023 | forbes.com
Hubei Biocause Pharmaceutical
March 3, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
February 10, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
January 19, 2023 | finance.yahoo.com
Advaxis and Ayala Pharmaceuticals Complete Merger
December 25, 2022 | finance.yahoo.com
Advaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo Finance
October 20, 2022 | streetinsider.com
Form 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.com
October 20, 2022 | finance.yahoo.com
RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo Finance
October 19, 2022 | marketscreener.com
ADVAXIS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K) - Marketscreener.com
October 19, 2022 | benzinga.com
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - Benzinga
October 19, 2022 | businesswire.com
AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
October 19, 2022 | baystreet.ca
Ayala, Advaxis Merge - Baystreet.ca
October 19, 2022 | marketwatch.com
Ayala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatch
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Company Calendar

Last Earnings
9/09/2021
Today
10/01/2023
Next Earnings (Estimated)
10/02/2023
Fiscal Year End
10/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADXS
CUSIP
N/A
CIK
1100397
Web
www.ayalapharma.com
Phone
609-452-9813
Fax
609-452-9818
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($8.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,360,000.00
Net Margins
N/A
Pretax Margin
-190,238.45%
Return on Equity
-248.72%
Return on Assets
-123.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.13
Quick Ratio
1.13

Sales & Book Value

Annual Sales
$250,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.01 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,820,000
Free Float
1,805,000
Market Cap
$1.45 million
Optionable
Not Optionable
Beta
2.34
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Kenneth A. Berlin J.D. (Age 59)
    Pres, CEO & Director
  • Mr. Igor Gitelman CPA (Age 47)
    CPA, M.B.A., MBA, Interim CFO & VP of Fin.
  • Dr. Shmuel Tuvia Ph.D.
    Chief Scientific Officer
  • Ms. Irit Klipper Avni M.A.
    VP of HR
  • Ms. Dana Gelbaum M.B.A. (Age 49)
    M.Sc., GM & Chief Bus. Officer
  • Dr. Andres A. Gutierrez M.D. (Age 62)
    Ph.D., Exec. VP & Chief Medical Officer

Key Competitors

View All Competitors













ADXS Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADXS shares.
View ADXS analyst ratings or view top-rated stocks.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 2nd 2023.
View our ADXS earnings forecast.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADXS."

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (NASDAQ:ADXS) has a market capitalization of $0.00 and generates $250,000.00 in revenue each year. The company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is 9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ 08852, United States. The official website for the company is www.ayalapharma.com. The company can be reached via phone at 609-452-9813, via email at ir@ayalapharma.com, or via fax at 609-452-9818.

This page (NASDAQ:ADXS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -